# Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

> **NCT07254793** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Arizona** · enrollment: 94 (estimated)

## Conditions studied

- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Acute Undifferentiated Leukemia (AUL)
- Myelodysplastic Syndrome
- Chronic Myeloid Leukemia
- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Exercise Mobilized Prophylactic DLI
- **BIOLOGICAL:** Standard Prophylactic DLI
- **BIOLOGICAL:** Exercise Mobilized Therapeutic DLI
- **BIOLOGICAL:** Standard Therapeutic DLI

## Key facts

- **NCT ID:** NCT07254793
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-31
- **Primary completion:** 2030-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07254793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07254793, "Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07254793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*